> ## Content Index
> Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Anupam Rasayan Buys Bliss GVS, With a ₹1 Option Attached
- URL: https://www.moatmarginresearch.com/anupam-rasayan-bliss-gvs-control/
- Published: 2026-09-29T16:30:14.000Z
- Updated: 2026-09-29T16:30:13.000Z
- Description: Anupam Rasayan now controls Bliss GVS Pharma. Investors funded most of the ₹1,750 crore, and Purebliss Pharma has a ₹1 option over the stake if the debt default
- Author: A K Karthikeyan
- Tags: Moat Insights

**Anupam Rasayan, a Surat specialty chemicals maker, now controls Bliss GVS Pharma, a branded medicines company. It paid ₹299 a share for about 48% of Bliss, around ₹1,524 crore. The strategy is clear: own the chain from raw materials to finished pills. The financing is the part to read closely. Outside investors led by Bain Capital put up most of the money, and the filings give Purebliss Pharma Solutions, the company that Anupam's subsidiary says it will raise the balance through, the right to buy the whole Bliss stake for ₹1 if the acquisition debt defaults.**

## What happened on 28 September

Anupam Rasayan said it "has paid the consideration towards the transaction of a 48.2% controlling stake in Bliss GVS Pharma Limited at ₹299 per share" (\[A\]). The buyer is Mates Visa Consultancy, Anupam's wholly owned subsidiary.

Bliss GVS's board then recorded the change (\[B1\], \[B2\]):

- Anupam Rasayan and Mates became promoters, holding 5,09,86,264 shares, or 47.95%;
- the open offer added only 1,669 shares;
- Managing Director Narsimha Kamath resigned, and three non-independent directors joined;
- the outgoing promoters, who held 34.82%, were reclassified as public shareholders.

At ₹299, the 5,09,84,595 shares bought from the sellers cost about ₹1,524 crore. Anupam says the price was "approximately 24x LTM earnings" (\[A\]).

The open offer barely moved. Asked about it in August, when an analyst noted the offer price was below the market price, Anupam's Vishal Thakkar said the shares tendered were "a very, very small number" (\[T\]).

## What Anupam is buying

Bliss GVS was founded in 1984\. It sells branded formulations, with "more than 150 brands" across anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, anti-diabetic and cardiovascular therapies. It has six plants in Maharashtra and calls itself "India's first EUGMP certified suppositories manufacturer" (\[A\]).

It is growing. In Q1 FY27 Bliss's consolidated revenue was ₹285.58 crore, up 38% from ₹207.47 crore a year earlier, and net profit was ₹51.37 crore against ₹44.36 crore (\[R\]). FY26 revenue was ₹927.11 crore.

Its plants are "currently operating at approximately 30% capacity" (\[A\]). Anupam's management told analysts in August: "we should be able to improve the utilization of the company's assets to 60% to 70%" (\[T\]). That is management's expectation, not a result.

## The strategy: one company from molecule to medicine

Anupam frames Bliss as the third of three acquisitions (\[A\]):

1. **Tanfac Industries** (2022) for fluorine raw materials, backward integration;
2. **Jayhawk Fine Chemicals**, Kansas (February 2026, enterprise value about US$134 million), for a US manufacturing base;
3. **Bliss GVS** for finished dosages, forward integration.

It says the combined group has pro-forma revenue of more than ₹4,000 crore and EBITDA of about ₹834 crore (\[A\]). Anupam on its own reported Q1 FY27 consolidated revenue of ₹667.5 crore, up 36%, and profit after tax of ₹51.2 crore (\[Q\]).

Management says it will leave Bliss's team in charge: "Anupam's approach towards any acquisition that we have done till date will be that we will continue to keep them as independent as they can be" (\[T\]).

## The financing: most of the money is someone else's

Anupam says the deal was funded by "a ₹300 crore term loan and approximately ₹1,450 crore raised through non-controlling, non-voting instruments from a group of financial investors led by Bain Capital and including Trust Group and Investec" (\[A\]). So about 83% of the ₹1,750 crore came from outside investors.

The September filings show how that works (\[S\], \[D\]):

- **The debt.** Mates issues up to ₹300 crore of senior secured NCDs. They are secured by a pledge of all of Mates' shares, a pledge of Anupam's 15% stake in Purebliss Pharma Solutions, and an unconditional guarantee from Anupam.
- **The equity-like money.** Mates "intends to raise the balance funds for the acquisition of securities of Bliss GVS Pharma Limited through proceeds of issuance of equity-like instruments to Purebliss Pharma Solutions Private Limited" (\[D\]).
- **The call option.** Anupam granted Purebliss an option to buy all of Mates' securities for ₹1.00\. It can be exercised on "identified event of default scenarios in connection with financing availed by MVCPL", after notice and cure periods (\[D\]).

Anupam's own explanation: "The INR 1 purchase consideration reflects the distressed-scenario nature of the trigger conditions" (\[D\]). It states that Purebliss is not a related party of the company (\[D\]). Mates holds the Bliss stake. If the option were exercised, control of Bliss would pass to Purebliss, in which Anupam holds 15%.

This is a security structure, and nothing in the filings suggests a default is in prospect. But a new owner's control of Bliss is, in the end, conditional on keeping its financing in good standing.

The parent is borrowing too. On 21 September Anupam issued ₹145 crore of NCDs to Aditya Birla Capital at 10.25%, maturing in 13 months (\[N\]).

## Moat and margin

**Focus moat: D3, cost advantage through integration.** Anupam's case is that owning each step, from fluorine chemistry to finished tablets and suppositories, lowers cost and lets it offer customers more of the chain. That is a D3 argument, and D3 is already Anupam's strongest dimension on the Moat Screener, at 7.0 (\[MS\]).

Bliss brings things that are hard to copy quickly: EU-GMP-certified plants, a suppositories niche, and more than 150 brands. What it adds to the margin depends on filling the plants. At 30% utilisation, every extra batch spreads fixed costs, which is why management keeps returning to the 60% to 70% figure.

The risk sits outside the moat. The ₹1 call option is D8, ungoverned risk: an event that could change who owns the asset, whatever the strength of the business. MoatSCORE tracks it but does not score it.

## MoatSCORE snapshot

| Company                                                                         | D1  | D2  | D3  | D4  | D5  | D6  | D7 | MoatSCORE      | Basis             |
| ------------------------------------------------------------------------------- | --- | --- | --- | --- | --- | --- | -- | -------------- | ----------------- |
| [Anupam Rasayan](https://www.moatmarginresearch.com/anupam-rasayan-india-moat/) | 4.8 | 5.7 | 7.0 | 5.5 | 5.5 | 6.0 | —  | 5.80           | AMBER, first pass |
| Bliss GVS Pharma                                                                |     |     |     |     |     |     |    | Not yet scored |                   |

As published on the Moat Screener on 29 September 2026 (\[MS\]). Anupam's score has not been re-scored for this acquisition.

## The bear case, taken seriously

- **Control is conditional.** If Mates' financing defaults and the cure period passes, Purebliss can buy the Bliss stake for ₹1 (\[D\]). Anupam's 15% of Purebliss is itself pledged to the same lenders.
- **The expensive money is unpriced in public.** The terms of the \~₹1,450 crore equity-like instruments are not in any filing read. Investors do not usually take 83% of the funding without a claim on the upside.
- **The multiple is full.** About 24 times trailing earnings for a formulations business, on Anupam's own figure (\[A\]).
- **The upside is a forecast.** Bliss at 60% to 70% utilisation is management's view, and Mr Thakkar declined to guide on Bliss before closing (\[T\]).
- **More debt at the parent.** 10.25% NCDs at Anupam, plus a guarantee of Mates' debt, add obligations to a company whose Q1 profit was ₹51.2 crore (\[N\], \[Q\]).
- **Three integrations at once.** Tanfac, Jayhawk and Bliss are each still being integrated.

## The case that it holds

- **The business is growing on its own.** Bliss's Q1 revenue rose 38%, and management called it "organic, is all I can say" (\[T\], \[R\]).
- **Most of the risk capital is someone else's.** Outside investors took most of the funding through non-voting instruments (\[A\]), leaving Anupam's own balance sheet with the ₹300 crore guarantee rather than the full ₹1,750 crore.
- **The option is standard security.** A ₹1 call on default is how lenders protect themselves. It matters only if the financing fails.
- **Anupam has done this before.** Tanfac, bought in 2022, now supplies its fluorine raw materials (\[A\]).

## What to watch

1. Any disclosure of Purebliss's shareholders or the terms of its instruments.
2. Bliss GVS's September-quarter results under new ownership, and utilisation.
3. Anupam's consolidated debt and interest cost once Bliss is included.
4. Any change to Bliss GVS's board or management beyond 28 September.
5. Refinancing or repayment of the Mates NCDs and the 13-month parent NCDs due October 2027.

## Sources

- **\[A\]** [Anupam Rasayan, press release: acquisition of Bliss GVS Pharma concluded, 28 Sep 2026](https://nsearchives.nseindia.com/corporate/ANURAS%5F28092026195741%5FARILSLDSTX20260928064PressRelease.pdf) (NSE)
- **\[B1\]** [Bliss GVS Pharma, board meeting outcome, 28 Sep 2026](https://nsearchives.nseindia.com/corporate/BLISSGVS%5F28092026204916%5FOutcome%5F%5F%5FBM%5F%5F%5FBliss%5FGVS%5F%5F%5F1%5FBoard%5FMeeting.pdf) (NSE)
- **\[B2\]** [Bliss GVS Pharma, second board meeting outcome, 28 Sep 2026](https://nsearchives.nseindia.com/corporate/BLISSGVS%5F28092026205539%5FOutcome%5F%5F%5FBM%5F%5F%5FBliss%5FGVS%5F%5F%5F2ndBM.pdf) (NSE)
- **\[S\]** [Anupam Rasayan, board outcome on Mates financing documents, 17 Sep 2026](https://nsearchives.nseindia.com/corporate/ANURAS%5F17092026205534%5FARILSLDSTX20260917060OutcomeofBM.pdf) (NSE)
- **\[D\]** [Anupam Rasayan, executed debenture, pledge, guarantee and call option documents, 23 Sep 2026](https://nsearchives.nseindia.com/corporate/ANURAS%5F23092026235444%5FARILSLDSTX20260923063Regulation30Disclosure.pdf) (NSE)
- **\[N\]** [Anupam Rasayan, allotment of NCDs, 21 Sep 2026](https://nsearchives.nseindia.com/corporate/ANURAS%5F21092026234016%5FARILSLDSTX20260921062AllotmentofNCDs.pdf) (NSE)
- **\[Q\]** [Anupam Rasayan, Q1 FY27 earnings press release, 14 Aug 2026](https://nsearchives.nseindia.com/corporate/ANURAS%5F14082026115931%5FARILSLDSTX20260814042PressRelease.pdf) (NSE)
- **\[T\]** [Anupam Rasayan, Q1 FY27 earnings call transcript](https://nsearchives.nseindia.com/corporate/ANURAS%5F20082026173857%5FARILSLDSTX20260820046Transcriptofearningscall.pdf) (NSE)
- **\[R\]** [Bliss GVS Pharma, Q1 FY27 results, 12 Aug 2026](https://nsearchives.nseindia.com/corporate/BLISSGVS%5F12082026193659%5FBM%5FOutcome%5F12082026.pdf) (NSE)
- **\[MS\]** [Moat & Margin, Moat Screener](https://www.moatmarginresearch.com/moat-screener/) and [How MoatSCORE works](https://www.moatmarginresearch.com/moatscore/)

---

> Educational research, not investment advice. Every figure above is drawn from Anupam Rasayan's and Bliss GVS Pharma's own filings, read from the primary documents on 29 September 2026\. The MoatSCORE is as published on the Moat Screener on that date. No buy/sell recommendations, no price targets. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.